Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 13/20 | 0.54 |
| ▸ | CTSS | P25774 | 11/20 | 0.51 |
| ▸ | CTSK | P43235 | 11/20 | 0.51 |
| ▸ | CTSB | P07858 | 10/20 | 0.51 |
| ▸ | GRN | P28799 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13726336 | 0.88 | CTSL (0.51) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL2376013 | 0.88 | CTSL (0.51) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL4419936 | 0.87 | CTSL (0.61) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL2131045 | 0.87 | CTSL (0.61) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL2130836 | 0.87 | CTSL (0.56) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL2130840 | 0.87 | CTSL (0.56) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL13624191 | 0.83 | CTSL (0.71) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL1272546 | 0.82 | CTSL (0.53) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL1272545 | 0.82 | CTSL (0.53) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL1272910 | 0.82 | KIF11 (0.56) | CTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | MERCK CANADA INC. (CA) | 2012-04-26 | — | — | US | disclosed |
| US-20090270511-A1 | PRODRUGS OF INHIBITORS OF CATHEPSIN S | MERCK FROSST CANADA LTD. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270511-A1 | PRODRUGS OF INHIBITORS OF CATHEPSIN S | CTSS, CTSF, CTSB | CTSL 10/4885CTSS 1/4885CTSK 7/4885 |
| US-20120101053-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES | CTSL, CTSS, CTSZ | CTSL 1/4885CTSS 2/4885CTSK 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.